Live: ACHEMA Opening Day Report - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Live: ACHEMA Opening Day Report



In 2009 there were 3767 exhibitors and more than 173000 visitors to ACHEMA in Frankfurt. The 2012 event looks to be even bigger. The hot topics for this year are energy and resources, while congress topics will address process engineering, pharmaceutical production and biotechnology. On the opening day, I saw a variety of new technologies for the pharma industry.

Lock showcased a gravity fall metal detection system that promises a greater product integrity for API manufacturers. They also have a bottlecheck system that incorporates an 'OPTIX' detector that inspects bottles of tablets and capsules at the end of the packaging line.

Thomas Homann of GEA showed me a separator for the recovery of vaccines and pharmaceutical proteins in lab scale and pilot plant applications. It operates at 20000G, which is unique worldwide. There are three bowl sizes, 15-30 L/h up to 150-300L/h. Of course, it is a sterile system that meets GMP requirements.

Merck Millipore have the only complete single-use process train that promises scalable, industry standard separation and purification technologies. The highest level of flexibility for multi-product, multi-scale facilities with modular units for scaling up, down and across unit operations.

More news to come soon!

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here